Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you need them, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should. These extra cells can form a mass called a tumor. Tumors can be benign or malignant. Benign tumors aren't cancer while malignant ones are. Cells from malignant tumors can invade nearby tissues. They can also break away and spread to other parts of the body.
Scientists from Weill Cornell Medicine and the New York Genome Center, in partnership with Oxford Nanopore Technologies, have introduced a new method for assessing the three-dimensional structure of the human genome, as well as how the genome folds, on a large scale.
In a paper that was just published in Science, scientists from Sweden’s Karolinska Institutet and SciLifeLab explain how they were able to enhance a protein’s capacity to repair oxidative DNA damage while also giving the protein a new role.
UT Southwestern researchers have developed nanoparticles that can penetrate the physical barriers that surround tumors and reach cancer cells.
The potential of CAR T-cell therapy for the treatment of solid tumors was unlocked in a preclinical trial by researchers at St. Jude Children’s Research Hospital who discovered a molecular mechanism. The findings were released in the journal Nature.
Cedars-Sinai Cancer Center scientists found that cancerous tumors known as soft-tissue sarcomas generate a protein that changes immune cells from tumor attacking to tumor-promoting.
The most frequent type of malignancy in kids is acute lymphoblastic leukemia (ALL).
Cancer cells can have thousands of mutations in their DNA. However, only a handful of those actually drive the progression of cancer; the rest are just along for the ride.
Biomedicines are produced by living cells and are used to treat cancer and autoimmune diseases among other things.
Professor Dr Anton Henssen of Charité – Universitätsmedizin Berlin and the Helmholtz Association’s Max Delbrück Center (MDC) for Molecular Medicine, along with a group of researchers from the United States and the United Kingdom, have received a grant for a Cancer Grand Challenge.
If you've ever swallowed the same round tablet in hopes of curing everything from stomach cramps to headaches, you already know that medicines aren't always designed to treat precise pain points.
Researchers have developed a unique 3D printed system for harvesting stem cells from bioreactors, offering the potential for high quality, wide-scale production of stem cells in Australia at a lower cost.
Researchers from Wake Forest University School of Medicine have discovered a possible new approach to treating solid tumors through the creation of a novel nanoparticle. Solid tumors are found in cancers such as breast, head and neck, and colon cancer.
Understanding how plants process light is key to improving crop yields. Light helps plants know when to grow and flower at the right time.
Funding will enable the development of Spirea’s pipeline of antibody drug conjugate therapeutics for the treatment of solid tumours.
Researchers at The University of Texas MD Anderson Cancer Center have developed a new approach to quantify tumor-specific total mRNA levels from patient tumor samples, which contain both cancer and non-cancer cells.
A new study presented at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga., suggests that probiotic bacteria may improve the anti-cancer actions of the breast cancer drug tamoxifen as well as other endocrine-targeted therapies, potentially lowering the risk of estrogen receptive positive (ER+) breast cancer.
To drive anabolic processes, epithelial ovarian cancer (EOC) is heavily reliant on the tricarboxylic acid (TCA) cycle and oxidative phosphorylation.
The three types of rotavirus that cause gastroenteritis in individuals, known as groups A, B, and C, are the most well-known and afflict predominantly youngsters.
The interferon-gamma receptor (IFNgR) signaling pathway has been identified to be crucial for the vulnerability of glioblastoma tumors to death by CAR T-cell immunotherapy, according to researchers at Massachusetts General Hospital (MGH).
The most prevalent type of cancer detected in women is breast cancer (BC). BC is the second biggest cause of death among female cancer patients globally.